Close

What are ADC's

Our services

ADC Review
is made possible by:




Can an ADC be Greater than the Sum of Its Parts?

The key components of antibody-drug conjugates or ADCs include a monoclonal antibody (mAbs), a stable linker and a cytotoxic (anticancer) agent. Monoclonal antibodies are attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. Antibody-drug conjugates are part of a specialized and technically challenging type of therapy combining innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.

After internalization, a cytotoxic small molecule drug is released within the cancer cell through a (bio)chemical process. [1]

References
[1] What are Antibody-drug Conjugates (ADCs)? ADC Review/J.Antibody-drug Conjugates. February 6, 2014 Article


This educational video was produced by Genentech, A Member of the Roche Group.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar